Key takeaway: The investor presentation from Entero Healthcare Solutions Limited reported a strong start to FY27, with consolidated revenue growth of 40.0% year-over-year (YoY) on a like-for-like basis, reaching INR 1,940 crore. Management highlighted improvements in EBITDA margins, which increased to 5.0%, and return ratios, with ROCE nearly doubling YoY to 21.1% and ROE to 20.4%. The presentation detailed that organic revenue growth was 19.6% YoY, while reported revenue growth was 38.2% YoY. Key financial metrics included a gross margin improvement of 147 basis points YoY to 11.4% and a PAT margin of 2.7%. Management noted no new acquisitions during the quarter, emphasizing organic growth and a strategic exit from low-margin businesses. The document also outlined the company's operational scale, with over 72,000 retail customers and 138 warehouses across India, positioning Entero as a significant player in the healthcare distribution market.

Key takeaway: Entero Healthcare Solutions Limited held its Q4 FY26 Earnings Conference Call on May 26, 2026, where management provided a comprehensive overview of the company's performance. Management reported a full-year revenue growth of 31.5% year-on-year, achieving a top line of INR 6,591 crores, and an EBITDA margin of 4%. The company highlighted its expansion into the MedTech sector, contributing over INR 1,000 crores in annualized revenue. For FY27, management set a goal of 23% revenue growth and 5% EBITDA margins, emphasizing a focus on organic growth and operational efficiencies. The call also addressed questions regarding minority interest, working capital, and the impact of acquisitions on future performance. Management expressed confidence in sustaining growth and improving margins, driven by a strong distribution network and strategic partnerships. The session concluded with an invitation for further inquiries from investors.

Key takeaway: The investor presentation from Entero Healthcare Solutions Limited reported significant progress in FY26, highlighting a vision to build a scalable healthcare distribution platform. Management noted a 31.5% like-for-like growth in revenue, with EBITDA margins expanding from 3.4% to 4.0%. The company achieved an operating cash flow of INR 96.2 Cr for the year, with a notable improvement in working capital efficiency. The presentation detailed that seven acquisitions were closed during the year, contributing to a proforma revenue of INR 1,025 Cr. For FY27, management set a goal of 23% revenue growth and a 5.0% EBITDA margin. The document emphasized the company's strategic focus on the MedTech segment, anticipating significant contributions from recent acquisitions. Overall, the presentation conveyed a strong performance across financial metrics and operational improvements.

Key takeaway: Management reported that Entero Healthcare Solutions Limited achieved a revenue growth of 26% year-on-year and 9% quarter-on-quarter for Q3 FY26, totaling INR 1,707 crores. Adjusted for certain factors, the like-to-like revenue growth was 28.5% year-on-year, with organic growth at 17.1%. Gross profit increased by 29% year-on-year, and EBITDA grew by 36% year-on-year, with a reported profit after tax of INR 34 crores, reflecting a 15% increase. Management highlighted improvements in working capital days, which decreased to 61 days, and operational cash flow of INR 49 crores for the quarter. The company also discussed its recent acquisitions in the MedTech segment, projecting significant revenue and margin enhancements post-integration. Management expressed confidence in achieving their FY26 guidance and emphasized a focus on consolidating recent acquisitions in the upcoming quarters.

Key takeaway: The investor presentation by Entero Healthcare Solutions Limited reported strong financial performance for the quarter and nine months ended December 31, 2025. Management highlighted a year-to-date organic like-for-like growth rate of 17.1% and a reported revenue growth of 25.6% year-over-year. The company generated INR 49 crore in operating cash flow during the quarter, maintaining an EBITDA margin of 4%. Key financial metrics included a gross margin improvement to 10.1% and a PAT margin of 2.0%, which adjusted for a one-off impact from the New Labour Code, was 2.3%. The presentation also noted the completion of several acquisitions, particularly in the Medtech segment, positioning the company for future growth. Management emphasized the strategic focus on enhancing cash flow and operational efficiency while expanding market presence through acquisitions.